GUTLAB – A SMART PILL FOR REMOTE HEALTH MONITORING VIA THE GUT MICROBIOME

GUTLAB — 通过肠道微生物组进行远程健康监测的智能药丸

• 批准号: 53074
• 金额: $ 14.89万
• 依托单位: ENTEROMICS LTD
• 依托单位国家: 英国
• 项目类别: Study
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=53074
• 关键词: GUTLAB; SMART; PILL; REMOTE; HEALTH

Enteromics are addressing the unmet challenge of longevity through developing a platform that enables remote health monitoring via the gut microbiome. The gut microbiome is crucial to health -- it affects your metabolism, immune system and even brain function. The food we eat, medications, exercise, sleep and stress all affect the gut microbiome and can cause it to become disrupted, leading to many diseases such as obesity, gut problems and even Alzheimer's. Enteromics is providing an ingestible smart sensing pill that tracks the microbiome and provides feedback to a smartphone App, in real-time.Enteromics is a start-up founded in 2019 by Phoebe Heseltine, a materials scientist and Mariam Elgabry, a biotechnologist. They are developing a range of smart pills to monitor and detect chronic diseases, beginning with Inflammatory Bowel Disease (IBD).Through this innovate UK Smart Grant, the core components of the ingestible device -- developed through the co-founders' initial research -- will be evaluated for safety and performance, in partnership with University College London. The work carried out in this grant is key to developing a strong IP position and determining the next steps to manufacturing, which will enable Enteromics to bring this technology to market.Exercise, nutrition, sleep and other lifestyle factors, as well as drug treatments offered, have an immediate effect on the gut microbiome and this provides a window of opportunity for better management of chronic conditions through continuous microbiome monitoring. If successful, the technology will outperform existing methods of sampling the microbiome such as faecal sampling, which are inconvenient, expensive and slow to provide results.The product will first launch in the UK to serve sufferers of IBD, a chronic relapsing gastrointestinal disorder for which there is no cure. IBD prevalence in the UK is second highest in the world, costing the NHS £720 million a year. Following successful launch in the UK the technology will be sold in North America, the fastest growing market for both ingestible sensors and microbiome products.Many sufferers seek repeated medical care for flare-ups, with frequent invasive medical exams, prescription of ineffective treatments and surgery. In IBD patients there is a very strong link between gut microbiome changes and disease flare-ups. With Enteromics' technology, individuals will be able to monitor their condition in a way that is medically safe, convenient and effective. Enteromics see their technology expanding into management of other chronic conditions as well as in consumer applications.

Enterobacterium正在通过开发一个平台来解决未满足的长寿挑战，该平台可以通过肠道微生物组进行远程健康监测。肠道微生物组对健康至关重要-它会影响您的新陈代谢，免疫系统甚至大脑功能。我们吃的食物，药物，运动，睡眠和压力都会影响肠道微生物组，并可能导致它被破坏，导致许多疾病，如肥胖，肠道问题，甚至阿尔茨海默氏症。Enterocalypse是一家初创公司，由材料科学家Phoebe Heseltine和生物技术专家Mariam Elgabry于2019年创立。Enterocalypse提供一种可摄入的智能传感药丸，可以实时跟踪微生物组并向智能手机应用程序提供反馈。他们正在开发一系列智能药丸来监测和检测慢性疾病，从炎症性肠病（IBD）开始。通过这项创新的英国智能赠款，可摄入设备的核心组件-通过联合创始人的初步研究开发-将与伦敦大学学院合作评估安全性和性能。在这项赠款中开展的工作是发展强大的知识产权地位和确定制造的下一步的关键，这将使Enterocaly能够将这项技术推向市场。运动，营养，睡眠和其他生活方式因素，以及提供的药物治疗，对肠道微生物组有直接的影响，这为通过持续的微生物组监测更好地管理慢性疾病提供了一个机会窗口。如果成功，该技术将优于现有的微生物组采样方法，如粪便采样，这些方法不方便，昂贵且提供结果缓慢。该产品将首先在英国推出，为IBD患者提供服务，IBD是一种慢性复发性胃肠道疾病，无法治愈。英国的IBD患病率在世界上排名第二，每年花费NHS 7.2亿英镑。在英国成功推出后，该技术将在北美销售，北美是可摄入传感器和微生物组产品增长最快的市场。许多患者因突发疾病而寻求反复的医疗护理，频繁的侵入性医学检查，无效的治疗处方和手术。在IBD患者中，肠道微生物组变化与疾病发作之间存在非常强的联系。有了Enterocaly的技术，个人将能够以一种医学上安全、方便和有效的方式监测自己的病情。Enteromics看到他们的技术扩展到其他慢性病的管理以及消费者应用中。